Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Mult Scler. 2023 May;29(6):741-747. doi: 10.1177/13524585231162586. Epub 2023 May 6.
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by two major and interconnected hallmarks: inflammation and progressive neurodegeneration.
The aim of this work was to compare neurodegenerative processes, in the form of global and regional brain volume loss rates, in healthy controls (HCs) and in patients with relapsing MS (RMS) treated with ocrelizumab, which suppresses acute inflammation.
Whole brain, white matter, cortical gray matter, thalamic, and cerebellar volume loss rates were assessed in 44 HCs that were part of a substudy in the OPERA II randomized controlled trial (NCT01412333) and 59 patients with RMS enrolled in the same substudy as well as age- and sex-matched patients in OPERA I (NCT01247324) and II. Volume loss rates were computed using random coefficients models over a period of 2 years.
Ocrelizumab-treated patients showed global and regional brain volume loss rates that were approaching that of HCs.
These findings are consistent with an important role of inflammation on overall tissue loss and the role of ocrelizumab in reducing this phenomenon.
多发性硬化症（MS）是一种中枢神经系统的慢性自身免疫性疾病，其特征是两个主要且相互关联的特征：炎症和进行性神经退行性变。
本研究旨在比较健康对照者（HCs）和接受奥瑞珠单抗治疗的复发型多发性硬化症（RMS）患者的神经退行性过程，奥瑞珠单抗可抑制急性炎症。
评估了 44 名作为 OPERA II 随机对照试验（NCT01412333）子研究一部分的 HCs 和 59 名来自同一子研究的 RMS 患者以及与年龄和性别匹配的 OPERA I（NCT01247324）和 II 中的患者的全脑、白质、皮质灰质、丘脑和小脑体积损失率。在 2 年期间，使用随机系数模型计算体积损失率。
奥瑞珠单抗治疗的患者的全脑和区域脑体积损失率接近 HCs。
这些发现与炎症对整体组织丢失的重要作用以及奥瑞珠单抗在减少这种现象的作用一致。
